Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Traws Pharma (TRAW) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $4.1 million.

  • Traws Pharma's Operating Expenses fell 5281.04% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 8685.96%. This contributed to the annual value of $142.6 million for FY2024, which is 59479.63% up from last year.
  • According to the latest figures from Q3 2025, Traws Pharma's Operating Expenses is $4.1 million, which was down 5281.04% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Traws Pharma's Operating Expenses peaked at $123.4 million during Q2 2024, and registered a low of $3.8 million during Q4 2021.
  • Over the past 5 years, Traws Pharma's median Operating Expenses value was $4.7 million (recorded in 2021), while the average stood at $11.2 million.
  • Per our database at Business Quant, Traws Pharma's Operating Expenses surged by 254420.4% in 2024 and then crashed by 9677.32% in 2025.
  • Traws Pharma's Operating Expenses (Quarter) stood at $3.8 million in 2021, then surged by 51.61% to $5.8 million in 2022, then fell by 21.97% to $4.5 million in 2023, then rose by 18.06% to $5.3 million in 2024, then decreased by 23.98% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $4.0 million for Q2 2025, and $5.3 million during Q1 2025.